40 Participants Needed

Dupilumab for Atopic Dermatitis

Recruiting at 2 trial locations
AB
DC
Overseen ByDermatology CTU
Age: < 18
Sex: Any
Trial Phase: Phase 4
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Must be taking: Inhaled corticosteroids, topical steroids
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

Will I have to stop taking my current medications?

The trial does not specify if you need to stop your current medications, but you must be on a stable regimen of inhaled corticosteroids, topical steroids, and antihistamines for at least 14 days before starting the study. You cannot use systemic immunosuppressants within 30 days of the first sleep study.

What data supports the effectiveness of the drug Dupilumab for treating atopic dermatitis?

Dupilumab has been shown to be effective and safe for treating moderate to severe atopic dermatitis in both clinical trials and real-world settings, with significant improvements observed in many patients.12345

Is dupilumab safe for humans?

Dupilumab is generally considered safe for treating atopic dermatitis, but some patients may experience side effects like eye issues and local skin infections. It has a better safety profile compared to some other treatments, but injection-site reactions and conjunctivitis (eye inflammation) are noted as common side effects.23678

What makes the drug Dupilumab unique for treating atopic dermatitis?

Dupilumab is unique because it is the first biologic drug specifically approved for moderate-to-severe atopic dermatitis, working by blocking the IL-4/IL-13 receptor to reduce type 2 inflammation, which helps improve the skin barrier and immune response.125910

Research Team

Amy S Paller: Faculty Profiles ...

Amy Paller

Principal Investigator

Lurie Children's Hospital/Northwestern University

Eligibility Criteria

Children aged 6-17 with moderate to severe atopic dermatitis (AD) that isn't well-controlled by topical treatments can join. They must have a history of sleep disturbances due to AD and be on stable medication regimens. Kids who've used certain meds recently, have other conditions affecting sleep, or cannot communicate in English are excluded.

Inclusion Criteria

You have trouble sleeping, as assessed by a specific test, or if you're under 8 years old, your parent has reported that you have trouble sleeping.
I have been on a stable dose of inhaled or topical steroids and antihistamines for at least 14 days.
I am between 6 and 17 years old.
See 3 more

Exclusion Criteria

Pregnancy
You are taking a medication that makes you feel itchy.
I can communicate in English.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive dupilumab treatment for 12 weeks with weekly subcutaneous injections

12 weeks
2 overnight visits (in-person) for sleep studies, weekly home administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Dupilumab
Trial OverviewThe trial is testing Dupilumab's effects over 12 weeks on improving circadian function, sleep quality, and itchiness in children with AD. It's an open-label study where all participants know they're receiving the drug and their sleep and itching symptoms are monitored before and after treatment.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Dupilumab administrationExperimental Treatment1 Intervention
dupilumab administered in weight based dosage for 12 weeks. The drug will be administered once a week during this time through a subcutaneous injection.

Dupilumab is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Dupixent for:
  • Atopic dermatitis
  • Asthma
  • Chronic rhinosinusitis with nasal polyps
  • Eosinophilic esophagitis
🇪🇺
Approved in European Union as Dupixent for:
  • Atopic dermatitis
  • Asthma
  • Chronic rhinosinusitis with nasal polyps
  • Eosinophilic esophagitis

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ann & Robert H Lurie Children's Hospital of Chicago

Lead Sponsor

Trials
275
Recruited
5,182,000+

Northwestern University

Lead Sponsor

Trials
1,674
Recruited
989,000+

Regeneron Pharmaceuticals

Industry Sponsor

Trials
690
Recruited
948,000+
Founded
1988
Headquarters
Tarrytown, USA
Known For
Precision medicine
Top Products
Dupixent, EYLEA, Libtayo, Praluent
Leonard Schleifer profile image

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos profile image

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School

Findings from Research

Dupilumab is an effective treatment for atopic dermatitis, showing significant improvements in skin symptoms and overall disease control in clinical trials.
The medication works by inhibiting specific pathways in the immune system, which helps reduce inflammation and alleviate the symptoms of atopic dermatitis.
Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.D'Ippolito, D., Pisano, M.[2020]
In a study of 100 patients with atopic dermatitis, 36% of those treated with dupilumab developed ocular diseases, significantly higher than the 10% in the reference group.
Severe allergic conjunctivitis and blepharitis were notably more common in the dupilumab group, with 30% and 22% of patients affected, respectively, indicating a need for careful monitoring and potential ophthalmologist consultation before starting treatment.
Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.Barbé, J., Poreaux, C., Remen, T., et al.[2021]
In a real-life study of 241 adults with atopic dermatitis treated with dupilumab, significant improvements were observed in skin severity scores after 3 months, with 48.8% of patients achieving a ≥75% improvement in the Eczema Area and Severity Index (EASI).
However, the study also found a higher incidence of conjunctivitis (38.2% of patients) and increased eosinophilia (57% during follow-up) compared to baseline, indicating potential safety concerns associated with dupilumab treatment.
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.Faiz, S., Giovannelli, J., Podevin, C., et al.[2019]

References

Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. [2020]
Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study. [2021]
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. [2019]
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. [2021]
Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. [2021]
Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients. [2023]
Dupilumab for treatment of atopic dermatitis. [2019]
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. [2021]
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study. [2023]
Dupilumab for the treatment of adolescents with atopic dermatitis. [2021]